Institution Directory

Clinical trials at UPMC (University of Pittsburgh)

Sites in Pittsburgh, PA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 2:08 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1600

Shown on this page

Current sort

Live official records

Conditions: Colorectal Carcinoma, Endometrial Carcinoma, Melanoma, Neuroblastoma, Ovarian Carcinoma, Pancreatic Ductal Adenocarcinoma, Recurrent Desmoid Fibromatosis, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Hepatocellular Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Refractory Desmoid Fibromatosis, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Hepatocellular Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Solid Pseudopapillary Neoplasm of the Pancreas, Wilms Tumor
Interventions: Biospecimen Collection, Dual X-ray Absorptiometry, Tegavivint, X-Ray Imaging; Procedure · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 12 Months to 30 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 21
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 18 more

Conditions: Adrenal Gland Pheochromocytoma, Carcinoma In Situ, Central Nervous System Neoplasm, Childhood Immature Teratoma, Childhood Kidney Neoplasm, Childhood Langerhans Cell Histiocytosis, Childhood Mature Teratoma, Congenital Mesoblastic Nephroma, Desmoid Fibromatosis, Ganglioneuroma, Lymphoproliferative Disorder, Malignant Neoplasm, Malignant Solid Neoplasm, Melanocytic Neoplasm, Myeloproliferative Neoplasm, Neoplasm of Uncertain Malignant Potential, Neuroendocrine Neoplasm, Stromal Neoplasm
Interventions: Cytology Specimen Collection Procedure, Medical Chart Review; Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 25 Years
Enrollment: 75,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2030
U.S. locations: 246
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 177 more

Conditions: Down Syndrome, Obstructive Sleep Apnea
Interventions: Inspire Upper Airway Stimulation (UAS) System; Device
Lead sponsor: Inspire Medical Systems, Inc.; Industry
Eligibility: 10 Years to 21 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 8
States / cities: Atlanta, Georgia • Boston, Massachusetts • Cincinnati, Ohio + 5 more

Conditions: Male Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma
Interventions: Tamoxifen, Anastrozole, Degarelix, Abemaciclib; Drug
Lead sponsor: Jose Pablo Leone; Other
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2036
U.S. locations: 9
States / cities: Washington D.C., District of Columbia • Jacksonville, Florida • Boston, Massachusetts + 6 more

Conditions: Chronic Kidney Disease Requiring Hemodialysis
Interventions: Technology Assisted Stepped Collaborative Care, Usual Care Arm; Behavioral · Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 424 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: Albuquerque, New Mexico • Pittsburgh, Pennsylvania

Conditions: Non-muscle Invasive Bladder Cancer
Interventions: TARA-002; Biological
Lead sponsor: Protara Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 44
States / cities: Homewood, Alabama • Phoenix, Arizona • Queen Creek, Arizona + 38 more

Conditions: Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions: Cytarabine, Flotetuzumab; Drug · Biological
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 20 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 19
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 16 more

Conditions: Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
Interventions: Atezolizumab, Biospecimen Collection, Computed Tomography, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging; Drug · Procedure · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 170
States / cities: Birmingham, Alabama • Anchorage, Alaska • Jonesboro, Arkansas + 107 more

Conditions: Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Ipatasertib, Magnetic Resonance Imaging, Paclitaxel; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 207
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 167 more

Conditions: Obesity, Overweight
Interventions: Orforglipron, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 12
States / cities: Oxnard, California • Stamford, Connecticut • Atlanta, Georgia + 8 more

Conditions: Advanced Colorectal Carcinoma, Advanced Digestive System Carcinoma, Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Colorectal Carcinoma, Metastatic Digestive System Carcinoma, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing, Elimusertib, Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 10
States / cities: Duarte, California • Bethesda, Maryland • City of Saint Peters, Missouri + 4 more

Conditions: HIV
Interventions: VRC07-523LS 400mg, PGT121.414.LS 400mg, PGDM1400LS 400mg, VRC07-523LS 3200mg, PGT121.414.LS 1600mg, PGDM1400LS 1600mg; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 13
States / cities: Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 8 more

About this UPMC (University of Pittsburgh) institution page

What this page lists: ClinicalTrials.gov records that list UPMC (University of Pittsburgh) in Pittsburgh, PA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at UPMC (University of Pittsburgh)

Filter and sort this campus

Live official records

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Project: Every Child for Younger Patients With Cancer

Effects of Hypoglossal Nerve Stimulation on Cognition and Language in Down Syndrome and Obstructive Sleep Apnea

ETHAN - ET for Male BC

Technology Assisted Collaborative Care Intervention to Improve Patient-centered Outcomes in Dialysis Patients

Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia

Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients

Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial

A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines

A Study of VRC07-523LS, PGT121.414.LS, and PGDM1400LS Broadly Neutralizing Monoclonal Antibodies Given Intravenously in Adult Participants Without HIV

About this UPMC (University of Pittsburgh) institution page